- Home
- MNDO vs STTK Comparison
MNDO vs STTK Comparison
Compare MNDO & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNDO
- STTK
- Stock Information
- Founded
- MNDO 1995
- STTK 2016
- Country
- MNDO Israel
- STTK United States
- Employees
- MNDO N/A
- STTK N/A
- Industry
- MNDO EDP Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- MNDO Technology
- STTK Health Care
- Exchange
- MNDO Nasdaq
- STTK Nasdaq
- Market Cap
- MNDO 34.2M
- STTK 37.6M
- IPO Year
- MNDO 2000
- STTK 2020
- Fundamental
- Price
- MNDO $1.34
- STTK $0.79
- Analyst Decision
- MNDO
- STTK Hold
- Analyst Count
- MNDO 0
- STTK 4
- Target Price
- MNDO N/A
- STTK $3.00
- AVG Volume (30 Days)
- MNDO 40.6K
- STTK 385.8K
- Earning Date
- MNDO 08-05-2025
- STTK 07-31-2025
- Dividend Yield
- MNDO 16.06%
- STTK N/A
- EPS Growth
- MNDO N/A
- STTK N/A
- EPS
- MNDO 0.17
- STTK N/A
- Revenue
- MNDO $20,677,000.00
- STTK $4,606,000.00
- Revenue This Year
- MNDO N/A
- STTK N/A
- Revenue Next Year
- MNDO N/A
- STTK N/A
- P/E Ratio
- MNDO $7.79
- STTK N/A
- Revenue Growth
- MNDO N/A
- STTK 69.65
- 52 Week Low
- MNDO $1.31
- STTK $0.69
- 52 Week High
- MNDO $2.13
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- MNDO 30.99
- STTK 38.78
- Support Level
- MNDO $1.33
- STTK $0.85
- Resistance Level
- MNDO $1.37
- STTK $1.14
- Average True Range (ATR)
- MNDO 0.03
- STTK 0.08
- MACD
- MNDO -0.00
- STTK -0.02
- Stochastic Oscillator
- MNDO 11.11
- STTK 1.60
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.